查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
奧沙利鉑市場規模、競爭格局和市場預測——2029 年
市場調查報告書
商品編碼
1156072

奧沙利鉑市場規模、競爭格局和市場預測——2029 年

Oxaliplatin Market Size, Competitive Landscape and Market Forecast - 2029
出版日期: | 出版商: DataM Intelligence | 英文 | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

市場概覽

奧沙利鉑是一種抗癌藥物，適用於治療結直腸癌。它是一種鉑類藥物，與順鉑和卡鉑類似。奧沙利鉑的作用是乾擾細胞中 DNA 的發育，阻止它分裂成新細胞並導致細胞死亡。

奧沙利鉑市場動態

奧沙利鉑市場的增長預計將受到結直腸癌發病率增加、生活方式改變、老年人口增加、腫瘤領域廣泛研究等因素的推動，從而在預測期內提振全球奧沙利鉑市場。預計是主要因素。

結直腸癌發病率上升預計將在預測期內推動全球奧沙利鉑市場

全球結直腸癌病例數正在增加。美國癌症協會 (ACS) 估計，2019 年美國將登記約 101,420 例結腸癌新病例和約 44,180 例直腸癌新病例。根據國家癌症研究所的數據，2018 年英國診斷出約 1,735,350 例新癌症病例。到 2037 年，意外診斷出的結直腸癌病例預計將增加 27.3%，達到 672,400 例。這種增加歸因於低纖維飲食、肥胖、酒精和煙草消費。結直腸病例數量的增加將刺激整個全球奧沙利鉑市場。

越來越多地使用生物製劑和靶向療法可能會阻礙全球結直腸癌藥物市場

生物製劑和靶向療法的使用增加可能會阻礙市場增長。生物療法幫助身體的免疫系統對抗癌症，而不是削弱身體免疫系統的化學物質。靶向治療可以阻止結直腸癌的生長和轉移，即使是在化學藥物不起作用的 IV 期。例如，FDA批准了用於治療結直腸癌的靶向療法，例如貝伐珠單抗、西妥昔單抗和帕尼單抗。生物製劑和靶向療法相對於傳統化學品的優越性可能會對市場產生負面影響。

COVID-19 影響分析

由於 COVID-19 大流行的爆發，全球奧沙利鉑市場由於生產和銷售環節的壁壘而下滑。疫情導致藥品生產減少，因為除口罩、消毒劑和換氣扇外，所有藥品都已關閉。所以在這次大流行期間，製造的藥品數量比以前少了。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 第 3 章：按配方類型劃分的市場細分
  • 按適應症劃分的市場細分
  • 按應用劃分的市場細分
  • 按分銷渠道細分的市場
  • 按地區劃分的市場細分

第四章市場動態

  • 市場影響因素
    • 司機
      • 結直腸癌的發病率增加
    • 約束
      • 增加生物製劑和靶向療法的使用
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 害蟲分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足需求分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章，按配方類型分類

  • 凍乾粉
  • 水溶液

第八章按功效

  • III 期結腸癌的輔助治療
  • IV 期結直腸癌藥物
  • 其他

第9章應用

  • 結腸癌
  • 胃癌
  • 卵巢癌

第 10 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的重點公司
  • 擁有顛覆性技術的公司
  • 初創公司

第 13 章全球奧沙利鉑市場：公司概況

  • Pfizer Inc
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Sanofi
  • Fresenius Kabi D
  • Dr. Reddy's laboratory
  • Sun Pharmaceutical Industries Ltd
  • Qilu Pharmaceutical Co., Ltd
  • Teva Pharmaceuticals USA, Inc
  • Jiangsu Aosaikang Pharmaceutical Co. Ltd
  • Mylan
  • Hospira
  • Nanjing Phamaceutical Factory
  • Jiangsu Hengrui Medicine
  • Lunan Pharmaceutical
  • Hisun Pharmaceutical
  • Hainan Jinrui Pharmaceutical

第14章 DataM

Market Overview

The global Oxaliplatin market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Oxaliplatin is an anti-cancer medication indicated to treat colorectal cancer. It is a platinum-based drug belonging to the same family as that of cisplatin and carboplatin. Oxaliplatin acts by interfering with the development of DNA in a cell, thereby stopping it from dividing into new cells and kills it.

Oxaliplatin Market Dynamics

The oxaliplatin market growth is driven by the growing incidence of Colorectal cancers, and changing lifestyle, increasing geriatric population and extensive research in field of oncology are the major factors that are anticipated to boost the global oxaliplatin market during the forecast period.

Increasing incidence of Colorectal Cancers, is expected to drive the global oxaliplatin market during the forecast period.

The number of colorectal cancer cases worldwide has been increasing. As per the American Cancer Society (ACS) estimates, there will be around 101,420 new colon cancer cases, and around 44,180 new cases of rectal cancer are registered in the USA in 2019. As per the National Cancer Institute data, nearly 1,735,350 new cases of cancer were diagnosed in the U.K in 2018. The diagnosed incident colorectal cancer cases are expected to increase by 27.3% to 672,400 cases by 2037. This increase can be attributed to a low-fiber diet, obesity, alcohol, and tobacco consumption. The increase in the number of colorectal cases will add to the overall global oxaliplatin market.

Increased usage of biologics and targeted therapies is likely to hamper the global colorectal cancer drugs market.

Increased usage of biologics and targeted therapies is likely to hamper the market growth. Biologic therapy helps the body's immune system fight against cancer rather than chemical drugs, which reduces the body's immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV, where chemical drugs are ineffective. For instance, the FDA has approved some targeted therapies to treat colorectal cancer, including bevacizumab, cetuximab, and panitumumab. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the market for global oxaliplatin market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the drugs were manufactured less compared to previous years, during the outbreak.

Segment Analysis

The lyophilized powder segment is expected to hold largest share in this market segment

Lyophilization is a freeze-drying process, which is performed to extend the shelf life of a product. The oxaliplatin lyophilized powder injection is prepared using a specific lyophilization process to increase the stability of the drug, reduce the risk of side effects, and ensure a high degree of clinical usage. However, it is slightly expensive than the aqueous solution. The global average selling price of 100 mg intravenous injection is around USD 84 - USD 500. Sanofi offers ELOXATIN in a lyophilized powder form.

The adjuvant treatment of stage III colon cancer segment is expected to hold largest share in this market segment

In patients with stage III colon cancer, adjuvant chemotherapy with fluoropyrimidine combined with oxaliplatin (FOLFOX and XELOX) are considered the standard treatment and reduces the risk of recurrence and mortality, with a treatment duration that may be shortened from 6 to 3 months in certain situations allowing to limit toxicities, especially cumulative sensitive neuropathy.

The colorectal cancer segment is expected to hold largest share in this market segment

Colorectal cancer is the second leading cause of cancer deaths in the U.S. As per the data by the National Cancer Institute, nearly 1,735,350 new cases of cancer were diagnosed in the U.K. and 609,640 people were succumbed to the disease in 2018. According to the American Society of Clinical Oncology (ASCO), in 2019, nearly 45,600 adults in the U.S. were diagnosed with colorectal cancer.

The hospital pharmacies segment is expected to hold largest share in this market segment

The hospital pharmacies held the largest share in the global oxaliplatin market. This is mainly owing to increasing number of patients suffering from colorectal cancers which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, Increasing number of oncologists and healthcare professionals, specializing in the diagnosis of cancer at an early stage and providing proper treatment is also contributing to the growth of this segment.Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.

Geographical Analysis

North America region holds the largest market share of global oxaliplatin market

North America held a major share of the global oxaliplatin market and is expected to continue its dominance during the forecast period. In North America, the oxaliplatin market is projected to be driven by an increase in colorectal cancer cases and raising awareness of various treatment modalities for cancer. As per the U.S. Department of Health and Human Services in U.S., colorectal cancer represented 8.3% of all new cancer cases in 2019. According to the American Cancer Society, Inc. (ACS), in 2020, nearly 104,610 new colon and 43,340 cases of rectal cancer are expected to be diagnosed in the U.S., with nearly 53,200 deaths from colorectal cancer.

Competitive Landscape

The global oxaliplatin market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Sanofi, Pfizer Inc, Fresenius Kabi D, Dr. Reddy's laboratory, Sun Pharmaceutical Industries Ltd, Qilu Pharmaceutical Co., Ltd, Teva Pharmaceuticals USA, Inc, Jiangsu Aosaikang Pharmaceutical Co. Ltd, Mylan, Hospira, Nanjing Phamaceutical Factory, Jiangsu Hengrui Medicine, Lunan Pharmaceutical, Hisun Pharmaceutical, Hainan Jinrui Pharmaceutical. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

Oxaliplatin Market Key Companies to Watch:

Pfizer Inc.

  • Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
  • Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
  • Product: OXALIPLATIN injection, for intravenous use 50 mg (5 mg/mL) or 100 mg (5 mg/mL) in a single-dose vial for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and treatment of advanced colorectal cancer.

Why Purchase the Report?

  • Visualize the composition of the oxaliplatin market segmentation by formulation type, application, indication, distribution channel and by region highlighting the key commercial assets and players.
  • Identify commercial opportunities in oxaliplatin market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of oxaliplatin market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global oxaliplatin market report would provide an access to an approx. 69 market data table, 61 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Formulation Type
  • 3.2. Market Snippet by Indication
  • 3.3. Market Snippet by Application
  • 3.4. Market Snippet by Distribution channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Increasing incidence of Colorectal Cancers
    • 4.1.2. Restraints:
      • 4.1.2.1. Increased usage of biologics and targeted therapies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Formulation Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation type Segment
    • 7.1.2. Market Attractiveness Index, By Formulation type Segment
  • 7.2. Lyophilized Powder*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Aqueous Solutions

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Segment
    • 8.1.2. Market Attractiveness Index, By Indication Segment
  • 8.2. Adjuvant Treatment of Stage III Colon Cancer*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Treatment of Stage IV Colorectal Cancer
  • 8.4. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Colorectal Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Stomach cancer
  • 9.4. Ovarian cancer

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.1.2. Market Attractiveness Index, By Distribution channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. Key Companies to Watch
  • 12.5. Company with disruptive technology
  • 12.6. Start Up Companies

13. Global Oxaliplatin Market - Company Profiles

  • 13.1. Pfizer Inc*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Sanofi
  • 13.3. Fresenius Kabi D
  • 13.4. Dr. Reddy's laboratory
  • 13.5. Sun Pharmaceutical Industries Ltd
  • 13.6. Qilu Pharmaceutical Co., Ltd
  • 13.7. Teva Pharmaceuticals USA, Inc
  • 13.8. Jiangsu Aosaikang Pharmaceutical Co. Ltd
  • 13.9. Mylan
  • 13.10. Hospira
  • 13.11. Nanjing Phamaceutical Factory
  • 13.12. Jiangsu Hengrui Medicine
  • 13.13. Lunan Pharmaceutical
  • 13.14. Hisun Pharmaceutical
  • 13.15. Hainan Jinrui Pharmaceutical

*(LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 4.3. Contact Us

List of Tables

  • Table 1: Global Oxaliplatin Market Value, By Formulation Type, 2021,2025 & 2029($ Million)
  • Table 2: Global Oxaliplatin Market Value, By Application, 2021,2025 & 2029($ Million)
  • Table 3: Global Oxaliplatin Market Value, By Indication, 2021,2025 & 2029($ Million)
  • Table 4: Global Oxaliplatin Market Value, By Distribution Channel, 2021,2025 & 2029($ Million)
  • Table 5: Global Oxaliplatin Market Value, By Region, 2021,2025 & 2029($ Million)
  • Table 6: Global Oxaliplatin Market Value, By Formulation Type, 2021,2025 & 2029($ Million)
  • Table 7: Global Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
  • Table 8: Global Oxaliplatin Market Value, By Application, 2021,2025 & 2029($ Million)
  • Table 9: Global Oxaliplatin Market Value, By Application, 2018-2029($ Million)
  • Table 10: Global Oxaliplatin Market Value, By Indication, 2021,2025 & 2029($ Million)
  • Table 11: Global Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
  • Table 12: Global Oxaliplatin Market Value, By Distribution Channel, 2021,2025 & 2029($ Million)
  • Table 13: Global Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
  • Table 14: Global Oxaliplatin Market Value, By Region, 2021,2025 & 2029($ Million)
  • Table 15: Global Oxaliplatin Market Value, By Region, 2018-2029($ Million)
  • Table 16: North America Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
  • Table 17: North America Oxaliplatin Market Value, By Application, 2018-2029($ Million)
  • Table 18: North America Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
  • Table 19: North America Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
  • Table 20: North America Oxaliplatin Market Value, By Country, 2018-2029($ Million)
  • Table 21: South America Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
  • Table 22: South America Oxaliplatin Market Value, By Application, 2018-2029($ Million)
  • Table 23: South America Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
  • Table 24: South America Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
  • Table 25: South America Oxaliplatin Market Value, By Country, 2018-2029($ Million)
  • Table 26: Europe Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
  • Table 27: Europe Oxaliplatin Market Value, By Application, 2018-2029($ Million)
  • Table 28: Europe Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
  • Table 29: Europe Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
  • Table 30: Europe Oxaliplatin Market Value, By Country, 2018-2029($ Million)
  • Table 31: Asia-Pacific Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
  • Table 32: Asia-Pacific Oxaliplatin Market Value, By Application, 2018-2029($ Million)
  • Table 33: Asia-Pacific Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
  • Table 34: Asia-Pacific Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
  • Table 35: Asia-Pacific Oxaliplatin Market Value, By Country, 2018-2029($ Million)
  • Table 36: Middle East & Africa Oxaliplatin Market Value, By Formulation Type, 2018-2029($ Million)
  • Table 37: Middle East & Africa Oxaliplatin Market Value, By Application, 2018-2029($ Million)
  • Table 38: Middle East & Africa Oxaliplatin Market Value, By Indication, 2018-2029($ Million)
  • Table 39: Middle East & Africa Oxaliplatin Market Value, By Distribution Channel, 2018-2029($ Million)
  • Table 40: Pfizer Inc: Overview
  • Table 41: Pfizer Inc: Product Portfolio
  • Table 42: Pfizer Inc: Key Developments
  • Table 43: Fresenius Kabi D: Overview
  • Table 44: Fresenius Kabi D: Product Portfolio
  • Table 45: Fresenius Kabi D: Key Developments
  • Table 46: Sanofi: Overview
  • Table 47: Sanofi: Product Portfolio
  • Table 48: Sanofi: Key Developments
  • Table 49: Dr. Reddy's laboratory: Overview
  • Table 50: Dr. Reddy's laboratory: Product Portfolio
  • Table 51: Dr. Reddy's laboratory: Key Developments
  • Table 52: Sun Pharmaceutical Industries Ltd: Overview
  • Table 53: Sun Pharmaceutical Industries Ltd: Product Portfolio
  • Table 54: Sun Pharmaceutical Industries Ltd: Key Developments
  • Table 55: Qilu Pharmaceutical Co., Ltd: Overview
  • Table 56: Qilu Pharmaceutical Co., Ltd: Product Portfolio
  • Table 57: Qilu Pharmaceutical Co., Ltd: Key Developments
  • Table 58: Teva Pharmaceuticals USA, Inc: Overview
  • Table 59: Teva Pharmaceuticals USA, Inc: Product Portfolio
  • Table 60: Teva Pharmaceuticals USA, Inc: Key Developments
  • Table 61: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Overview
  • Table 62: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Product Portfolio
  • Table 63: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Key Developments
  • Table 64: Mylan: Overview
  • Table 65: Mylan: Product Portfolio
  • Table 66: Mylan: Key Developments
  • Table 67: Hospira: Overview
  • Table 68: Hospira: Product Portfolio
  • Table 69: Hospira: Key Developments

List of Figures

  • Figure 1: Global Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
  • Figure 2: Global Oxaliplatin Market Share, By Application, 2021 & 2029(%)
  • Figure 3: Global Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
  • Figure 4: Global Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
  • Figure 5: Global Oxaliplatin Market Share, By Region, 2021 & 2029(%)
  • Figure 6: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 7: Global Oxaliplatin Market Y-o-Y Growth, By Formulation Type, 2021 & 2029(%)
  • Figure 8: Lyophilized Powder: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 9: Aqueous Solutions: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 10: Global Oxaliplatin Market Y-o-Y Growth, By Application, 2021 & 2029(%)
  • Figure 11: Colorectal cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 12: Stomach Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 13: Ovarian Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 14: Global Oxaliplatin Market Y-o-Y Growth, By Indication, 2021 & 2029(%)
  • Figure 15: Adjuvant Treatment of Stage III Colon Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 16: Treatment of Stage IV Colorectal Cancer: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 17: Others: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 18: Global Oxaliplatin Market Y-o-Y Growth, By Distribution Channel, 2021 & 2029(%)
  • Figure 19: Hospital Pharmacies: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 20: Retail Pharmacies: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 21: Online Pharmacies: Global Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 22: Global Oxaliplatin Market Y-o-Y Growth, By Region, 2021 & 2029(%)
  • Figure 23: North America Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 24: North America Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
  • Figure 25: North America Oxaliplatin Market Share, By Application, 2021 & 2029(%)
  • Figure 26: North America Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
  • Figure 27: North America Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
  • Figure 28: North America Oxaliplatin Market Share, By Country, 2021 & 2029(%)
  • Figure 29: South America Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 30: South America Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
  • Figure 31: South America Oxaliplatin Market Share, By Application, 2021 & 2029(%)
  • Figure 32: South America Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
  • Figure 33: South America Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
  • Figure 34: South America Oxaliplatin Market Share, By Country, 2021 & 2029(%)
  • Figure 35: Europe Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 36: Europe Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
  • Figure 37: Europe Oxaliplatin Market Share, By Application, 2021 & 2029(%)
  • Figure 38: Europe Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
  • Figure 39: Europe Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
  • Figure 40: Europe Oxaliplatin Market Share, By Country, 2021 & 2029(%)
  • Figure 41: Asia-Pacific Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 42: Asia-Pacific Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
  • Figure 43: Asia-Pacific Oxaliplatin Market Share, By Application, 2021 & 2029(%)
  • Figure 44: Asia-Pacific Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
  • Figure 45: Asia-Pacific Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
  • Figure 46: Asia-Pacific Oxaliplatin Market Share, By Country, 2021 & 2029(%)
  • Figure 47: Middle East & Africa Oxaliplatin Market Value, 2018-2029($ Million)
  • Figure 48: Middle East & Africa Oxaliplatin Market Share, By Formulation Type, 2021 & 2029(%)
  • Figure 49: Middle East & Africa Oxaliplatin Market Share, By Application, 2021 & 2029(%)
  • Figure 50: Middle East & Africa Oxaliplatin Market Share, By Indication, 2021 & 2029(%)
  • Figure 51: Middle East & Africa Oxaliplatin Market Share, By Distribution Channel, 2021 & 2029(%)
  • Figure 52: Pfizer Inc: Financials
  • Figure 53: Fresenius Kabi D: Financials
  • Figure 54: Sanofi: Financials
  • Figure 55: Dr. Reddy's laboratory: Financials
  • Figure 56: Sun Pharmaceutical Industries Ltd: Financials
  • Figure 57: Qilu Pharmaceutical Co., Ltd: Financials
  • Figure 58: Teva Pharmaceuticals USA, Inc: Financials
  • Figure 59: Jiangsu Aosaikang Pharmaceutical Co. Ltd: Financials
  • Figure 60: Mylan: Financials
  • Figure 61: Hospira: Financials